Name: Targeted Cancer Immune Therapy (en Inglés)
SKU: 3108534
Price: 177.87 USD
Availability: InStock
Author: Lustgarten, Joseph ; Cui, Yan ; Li, Shulin

portada Targeted Cancer Immune Therapy (en Inglés)

Targeted Cancer Immune Therapy (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Lustgarten, Joseph ; Cui, Yan ; Li, Shulin

Idioma

Inglés

N° páginas

343

Encuadernación

Tapa Dura

Dimensiones

23.9x16.3x2.5 cm

Peso

0.77 kg.

ISBN

9781441901699

ISBN13

9781441901699

Categorías

Oncología
Farmacología

Targeted Cancer Immune Therapy (en Inglés)

Lustgarten, Joseph ; Cui, Yan ; Li, Shulin (Autor) · Springer · Tapa Dura

Libro Nuevo Importado

Envío: 20 a 27 días háb.

$ 355.74$ 177.87

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 177.87

Llega entre el 18 Sep y el 01 Oct a Quito, Pichincha. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Targeted Cancer Immune Therapy (en Inglés)"

Stimulation of the immune system's ability to control and destroy tumors cont- ues to be the goal of cancer immune therapy; but the scope has rapidly expanded; approaches are constantly updated; new molecules are continually introduced; and immune mechanisms are becoming better understood. This book has no intention of covering every aspect of immune therapy but rather focuses on the novelty of cancer immune therapy in an attempt to give readers an opportunity to absorb the new aspects of immune therapy from a single source. In this regard, three areas were selected: cytokine immune therapy, cell-based immune therapy, and targeted immune therapy. In each of these three sections, only the novel aspects of immune therapy were described instead of attempting to cover any historical achievement. In the first section, Cytokine Immune Therapy, the IL12 family, IL18, IL21, IL24, IL28, and IL29 were emphasized in regard to the an- tumor function and application in treating tumors. Most of these selected cyt- ines were discovered in last 10 years. In the second section, Cell-based Immune Therapy, the focus was engineering potent immune regulatory or effector cells such as dendritic cells, T cells, and stem cells. Cell engineering design is primarily based on the increased understanding of the interaction of tumor antigen-presenting cells, antigen- specific effector cells, and the tumor microenvironment.